These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32797729)

  • 1. A Bayesian time-to-event pharmacokinetic model for phase I dose-escalation trials with multiple schedules.
    Günhan BK; Weber S; Friede T
    Stat Med; 2020 Nov; 39(27):3986-4000. PubMed ID: 32797729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I dose-escalation oncology trials with sequential multiple schedules.
    Günhan BK; Weber S; Seroutou A; Friede T
    BMC Med Res Methodol; 2021 Apr; 21(1):69. PubMed ID: 33853539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Escalation strategies for combination therapy Phase I trials.
    Sweeting MJ; Mander AP
    Pharm Stat; 2012; 11(3):258-66. PubMed ID: 22411472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GUIP1: a R package for dose escalation strategies in phase I cancer clinical trials.
    Dinart D; Fraisse J; Tosi D; Mauguen A; Touraine C; Gourgou S; Le Deley MC; Bellera C; Mollevi C
    BMC Med Inform Decis Mak; 2020 Jun; 20(1):134. PubMed ID: 32580715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
    Du Y; Yin J; Sargent DJ; Mandrekar SJ
    J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.
    Muenz DG; Braun TM; Taylor JM
    Clin Trials; 2018 Aug; 15(4):386-397. PubMed ID: 29779418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian adaptive dose-escalation designs for simultaneously estimating the optimal and maximum safe dose based on safety and efficacy.
    Yeung WY; Reigner B; Beyer U; Diack C; Sabanés Bové D; Palermo G; Jaki T
    Pharm Stat; 2017 Nov; 16(6):396-413. PubMed ID: 28691311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.
    Tighiouart M; Rogatko A; Babb JS
    Stat Med; 2005 Jul; 24(14):2183-96. PubMed ID: 15909291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I design for completely or partially ordered treatment schedules.
    Wages NA; O'Quigley J; Conaway MR
    Stat Med; 2014 Feb; 33(4):569-79. PubMed ID: 24114957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escalation with overdose control for phase I drug-combination trials.
    Shi Y; Yin G
    Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity grades.
    Takeda K; Xia Q; Liu S; Rong A
    Pharm Stat; 2022 Mar; 21(2):496-506. PubMed ID: 34862715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
    Gerke O; Siedentop H
    Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials.
    Xie F; Ji Y; Tremmel L
    Contemp Clin Trials; 2012 Jul; 33(4):739-48. PubMed ID: 22426247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials.
    Chen Z; Yuan Y; Li Z; Kutner M; Owonikoko T; Curran WJ; Khuri F; Kowalski J
    Contemp Clin Trials; 2015 Jul; 43():133-41. PubMed ID: 26012358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical phase I dose-finding design with adaptive shrinking boundaries for drug combination trials.
    Li Z; Xu Z; Zhang A; Qi G; Li Z
    BMC Med Res Methodol; 2023 Mar; 23(1):57. PubMed ID: 36864387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized dose-escalation designs for drug combination cancer trials with immunotherapy.
    Mozgunov P; Jaki T; Paoletti X
    J Biopharm Stat; 2019; 29(2):359-377. PubMed ID: 30352007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian dose escalation with overdose and underdose control utilizing all toxicities in Phase I/II clinical trials.
    Tu J; Chen Z
    Biom J; 2024 Jan; 66(1):e2200189. PubMed ID: 38047521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving safety of the continual reassessment method via a modified allocation rule.
    Mozgunov P; Jaki T
    Stat Med; 2020 Mar; 39(7):906-922. PubMed ID: 31859399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials.
    Zhou Y; Zhao Y; Cicconetti G; Mu Y; Yuan Y; Wang L; Penugonda S; Salman Z
    Pharm Stat; 2023 Mar; 22(2):300-311. PubMed ID: 36333972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hybrid continuous reassessment method with overdose control for safer dose escalation.
    Ghosh D; Xie H; Zhang L; Chen F; Mohanty S; Li X
    J Biopharm Stat; 2023 Sep; 33(5):586-595. PubMed ID: 36715485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.